A Study of MKC-442 in Combination With Other Anti-HIV Drugs

Inclusion Criteria Concurrent Medication: Allowed: \- Based on medical history, medical condition, prior use of antiretroviral drugs, and genotypic analysis of the predominant strain of HIV-1 isolated from the plasma, administration of a combination of two or more available antiretroviral agents by prescription may be given with MKC-442. Patient must have: * HIV infection with HIV-1 RNA greater than or equal to 5,000 by Roche Amplicor method within 30 days of entry. * A failed protease inhibitor-containing regimen. * Negative serum beta human chorionic gonadotropin test within 30 days of entry. Prior Medication: Allowed: * Prior nucleoside reverse transcriptase and protease inhibitors. * Cytotoxic chemotherapy more than 30 days prior to entry. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Malabsorption or severe chronic diarrhea within 30 days prior to entry, or inability to consume adequate oral intake because of chronic nausea, emesis, or abdominal or esophageal discomfort. * Inadequately controlled seizure disorder. * Known intolerance to stavudine, didanosine, and/or hydroxyurea. * Acute and clinically significant medical event within 30 days of screening. * Any clinical or laboratory abnormality greater than Grade 3 toxicity, with the exception of laboratory values given. Concurrent Treatment: Excluded: \- Any experimental antiretroviral therapy or immunomodulators directed against HIV-1, e.g., IL-4, cyclosporine steroids at doses greater than 40 mg/day. Prior Medication: Excluded: \- Non-nucleoside reverse transcriptase inhibitor therapy. Prior Treatment: Excluded: * Radiation therapy within 30 days of entry except to a local lesion. * Transfusion of blood or blood products within 21 days of screening. * Cytotoxic therapy within 3 months of study entry. Risk Behavior: Excluded: Active substance abuse that may interfere with compliance or protocol evaluations.